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Saul-Wilson syndrome (SWS) is a rare autosomal recessive disorder characterized by 
microcephalic primordial dwarfism, spondyloepimetaphyseal dysplasia, characteristic 
facial findings, clubfoot, brachydactyly, bilateral cataracts, and hearing loss. Recently, 
recurrent mutations in COG4, encoding a component of the Conserved Oligomeric 
Golgi (COG) complex, were identified. We created detailed growth curves for stature, 
weight, and head circumference, as well as weight-for-length and weight velocity charts 
for younger children, derived from hundreds of data points obtained by retrospective 
chart review from 14 individuals with molecularly-confirmed SWS. In addition, we 
performed statistical comparisons of height-for-age model fits before and after initiation 
of growth hormone supplementation, and found that this therapy does not appear to 
influence height in individuals with SWS. We hope that these charts will represent 
valuable tools for clinicians, both in assessing whether SWS seems an appropriate 
diagnosis, as well as to monitor growth of affected individuals. In particular, we hope 
that our detailed growth characterization will reduce morbidity resulting from 
unnecessarily aggressive nutritional interventions by well-intentioned physicians trying 
to promote weight gain, an unrealistic goal in this genetically-determined cause of 
primordial dwarfism.
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Saul-Wilson syndrome (SWS) belongs to a group of disorders called microcephalic 
primordial dwarfism, characterized by pre- and postnatal growth deficiency, and 
microcephaly. Other than the aforementioned features of microcephalic primordial 
dwarfism, affected individuals also exhibit blue sclerae, large anterior fontanelle, a 
prominent forehead, clubfoot, brachydactyly, bilateral cataracts, rod-cone dystrophy, 
hearing loss, and characteristic radiographic findings (Hersh et al., 1994; R. A. Saul & 
Wilson, 1990; Robert A. Saul, 1982). Recently, a recurrent heterozygous amino acid 
substitution (p.Gly516Arg) in COG4 was identified in 14 patients (Ferreira et al., 2018). 
COG4 is a component of the Conserved Oligomeric Golgi (COG) complex, a multi-
subunit protein complex that participates in vesicular trafficking to and from the Golgi 
apparatus, and is essential for the latter’s structure and function (Ungar, Oka, Krieger, & 
Hughson, 2006). Fibroblasts from patients with Saul-Wilson syndrome demonstrate 
disruption of vesicular trafficking, Golgi morphology, and decorin glycosylation (Ferreira 
et al., 2018). 
As is the case with other types of microcephalic primordial dwarfism (Bober et al., 
2012), it is our experience that individuals with SWS undergo aggressive feeding 
regimens in early childhood, in an attempt to improve growth. This overfeeding does 
not, however, lead to improved growth parameters, since the cause of growth failure 
does not lie in undernutrition, but in the genetic nature of the condition. This 
phenomenon of overfeeding is partly caused by a lack of established reference curves 
for stature, weight, and head circumference for individuals affected with the syndrome. 
As growth failure represents such a prominent feature of SWS, the establishment of 
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normative growth curves would aid in the management of individuals with this condition, 
as well as in the diagnosis of patients with primordial dwarfism in general. Here, we 




Data was obtained from 6 females and 8 males with molecularly-confirmed SWS, 
ranging in age from infancy to 39 years old. Written informed consent was obtained 
from all affected individuals or their parents/legal guardians. All were enrolled in at least 
one of the following research protocols, which were approved by their respective 
institutional review boards: 14-HG-0071, “Clinical and Basic Investigations into Known 
and Suspected Congenital Disorders of Glycosylation”; 76-HG-0238, “Diagnosis and 
Treatment of Patients with Inborn Errors of Metabolism or other Genetic Disorders”;  
“Enquiry of Participation in a Research Project about Clinical and Molecular Studies on 
Rare Congenital Skeletal Disorders”; or 83142, “Primordial Registry at Nemours/Alfred I. 
duPont Hospital for Children.” 
Growth calculated as standard deviations
Standard deviations (SDs) for length/height, weight, and OFC normalized for age and 
gender were calculated using the 2000 Centers for Disease Control and Prevention 
(CDC) growth charts (Kuczmarski et al., 2002). In addition, growth parameters for birth 
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were calculated using the revised Fenton growth charts (Fenton & Kim, 2013). Data 
from Roche et al. was used for calculation of head circumference Z-scores in individuals 
older than 36 months (Roche, Mukherjee, Guo, & Moore, 1987). A Shapiro-Wilk 
normality test was performed for all growth parameters at birth and at last examination 
(not performed at skeletal maturity given the small number of patients, n=3). Given a 
normal distribution, an unpaired t test was subsequently performed comparing the mean 
Z-scores for each growth parameter against a mean Z-score of 0 for the control 
population. Statistical significance was assigned to a two-tailed p-value <0.05. Analysis 
was performed with Prism version 6.0c (Graphpad Software Inc, La Jolla, CA).
Growth charts
The growth pattern for stature, weight, and head circumference data sets (corrected for 
gestational age in case of preterm birth) were modeled using locally weighted 
scatterplot smoothing as implemented by the loess() function in R version 3.4.0 (R Core 
Team, 2017). The smoothness of fit when using loess() depends on a smoothing 
parameter; a higher smoothing parameter considers more points in the curve and 
results in smoother fits to the data, while a lower smoothing parameter will more 
precisely fit the data locally and the best fit curve will be rougher. In this case, the best 
smoothing parameter was estimated using leave-one-out k-fold cross-validation in order 
to minimize the root mean square error of the fit and fine-tuned to each dataset via 
visual inspection of the final generated growth curve (Lee & Cox, 2010). Then, using 20 
equally sized bins for ages between zero and three years, and 40 equally sized bins for 
ages between zero and 9-12.5 years (dependent on the data being modeled), loess() 
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was used to model the mean and loess.sd() from the msir package (Scrucca, 2011) to 
model the standard deviations for the variables of interest. Prediction intervals (90%, 
75%, and 50%) were obtained by multiplying the standard deviations by the usual 
multipliers (1.64, 1.15, and 0.67, respectively). Endpoint of data modeling occurred 
when there were either too few data so that loess() failed, or when trends fit by loess() 
turned non-physical (e.g., a downturn in mean head circumference in the teenage years 
as a result of single individuals representing the entire group when others dropped out 
of the cohort). Normative reference curves were taken from CDC references 
(Kuczmarski et al., 2002).
Growth hormone effect
In order to ascertain the effect of human growth hormone (HGH) treatment on height, 
single subject linear regression models using a square root fit of subjects’ height-for-age 
data were implemented, where pre-HGH versus post-HGH conditions were considered 
for each of the four subjects who received HGH therapy. These two models were then 
compared using analysis of variance (ANOVA). Where models were found to be 
significantly different, it was presumed that HGH treatment had an effect. For one 
subject (P6.1) who interrupted HGH therapy for approximately one year, model fits were 
divided so that each pre- and post-HGH condition could be compared via curve fits. 
Besides modeling individual subjects, models were also fit using height-for-age data 
from all subjects who never received HGH, and height-for-age data before initiation of 
HGH from subjects who eventually received this therapy. All statistics were performed 
using R version 3.5.2.  
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The data that supports the findings of this study (absolute growth parameters for all 
individuals) are available in Table S1. In total, there were 297 available data points for 
length/height, 416 data points for weight, and 129 data points for head circumference. 
Mean standard deviation scores of individuals with SWS at birth, at last examination and 
at skeletal maturity are presented in table 1. Comparison of birth length and birth weight 
Z-scores of individuals with SWS using CDC growth charts vs. prematurity-adjusted 
Fenton charts did not reveal a statistical significant difference (p-values 0.11 and 0.23, 
respectively); this is consistent with the fact that the mean gestational age for the whole 
cohort was 37 weeks 2 days, thus at term. When considering weight and length/height Z-
scores of SWS patients, there was strong statistical difference compared to the control 
population across all ages, as expected (p-values for length/height 0.002 at birth, 0.0001 
at last exam, 0.0026 at skeletal maturity; p-values for weight 0.0001 at birth and at last 
examination, 0.0069 at skeletal maturity). For birth head circumference in the SWS 
cohort, there was a statistically significant difference when using CDC growth charts 
versus preterm-adjusted Fenton charts (p-value 0.02). Thus, we chose to compare birth 
head circumference of the control population against the SWS cohort using Fenton 
charts, which interestingly did not reveal any statistical significance (p-value 0.13). 
However, comparison at a later age (at last examination of head circumference, mean 
age 9 years 6 months) did reveal a strong statistical difference between both groups (p-
value 0.0001), indicating progression to microcephaly as individuals grow older. 
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Correction for gestational age was not necessary for this comparison, since age at least 
measurement of head circumference was >2 years for all individuals born prematurely. 
Interestingly, while there is an absolute microcephaly present in many affected individuals 
during growth and at skeletal maturity, the head circumference in all individuals with SWS 
exceeds the height by more than 2 SD, with consequent relative macrocephaly. 
Table 2 presents growth parameters expressed as absolute values. The average birth 
length of affected individuals measured more than two weeks behind gestational age, 
while the average birth weight measured more than 3 weeks behind (mean gestational 
age at birth for males 37 weeks 1 day, mean gestational age at birth for females 37 weeks 
4 days). The average birth head circumference for females also measured more than two 
weeks behind gestational age, while for males it measured 1 week 6 days behind 
gestational age. 
Figure 1 presents growth curves for stature, weight and head circumference compared to 
the average population. Notably, although absolute microcephaly has been traditionally 
considered as a cardinal feature of Saul-Wilson syndrome, patients’ head circumferences 
vary and can overlap the lower end of the general population distribution. 
Growth charts without superimposition to average population standards, which can be 
used for monitoring growth of individuals with SWS, are included as supplementary 
figures S1-S6. 
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Weight velocity and weight-for-length charts are useful in assessing growth and 
estimating nutritional status in young children, and are thus presented in Figure 2. 
Four subjects received HGH supplementation, and its effect on growth was evaluated by 
comparing height-for-age model fits before and after initiation of therapy for each subject 
(Figure 3). In all cases, statistical comparisons of the model fits were not significant, with 
the following p-values: 0.489 for P1.1; 0.068 (first few years of HGH supplementation) 
and 0.071 (resumption of HGH after interruption of about one year) for P6.1; 0.411 for 
P9.1; and 0.052 for P10.1. Consequently, it appears that HGH does not improve height 
in individuals with SWS.
DISCUSSION
We provide a careful characterization of growth in individuals with SWS confirmed 
molecularly. We believe that this work will be important in estimating nutritional needs of 
individuals with SWS, by providing appropriate standards by which to base growth 
expectations. Additionally, and when used in conjunction with other clinical features, it 
will also serve as a tool in the differential diagnosis of microcephalic primordial 
dwarfism. Based on growth parameters alone, SWS is distinguishable from 
microcephalic osteodysplastic primordial dwarfism type II (MOPDII), one of the most 
common causes of microcephalic primordial dwarfism. The average birth length, weight, 
and head circumference (corrected for gestational age) in patients with MOPDII was -
7.0, -3.9, and -4.6 standard deviation scores from the population mean, much smaller at 
birth than patients with SWS (Bober et al., 2012). 
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An unexpected finding in our cohort is that head circumferences of individuals with Saul-
Wilson syndrome can overlap the lower end of the general population distribution. This 
may in part be explained by head circumference percentiles being overestimated with 
CDC growth charts (Daymont, Hwang, Feudtner, & Rubin, 2010), with a lesser degree 
of overlap seen with other head circumference growth curves. Nevertheless, Saul-
Wilson syndrome remains a microcephalic disorder for most affected individuals in 
absolute measurement terms, despite the appearance of relative macrocephaly. In fact, 
although head circumference was not statistically significantly different from the general 
population at birth, there was significant microcephaly that developed at a later age.
A potential limitation of our study is that a small number of individuals (with different 
number of measurements for each) were included for estimation of growth curves. 
Given this limitation, the growth data was not presented as percentiles but rather as 
prediction intervals, which estimate the likelihood that a future data point will fall within 
this interval. To generate the provided curves, one must make the assumption that 
these individuals are likely to be representative of the population of affected individuals. 
Therefore, our growth charts are provided with the expectation of assisting physicians in 
judging if future patients exhibit significant deviation from expected growth. In addition, 
we also provide actual data points in the supplementary table, as these absolute values 
might also prove useful in judging appropriate growth. While the curves provided were 
based on 14 individuals, hundreds of data points were used in each model to estimate 
prediction intervals. Ultimately, these curves are likely to be of diagnostic help when 
evaluating a child with primordial dwarfism at the bedside, and in monitoring growth of 
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molecularly-confirmed individuals in the clinic. 
In summary, we have carefully delineated the growth phenotype of SWS, creating 
growth charts that will be of assistance in the diagnosis of patients with primordial 
dwarfism in general, and in the management of individuals with SWS in particular. 
These charts will be useful in estimating nutritional needs of an individual with SWS by 
providing appropriate standards for comparison of growth parameters, and will thus 
likely decrease the risk of unnecessarily aggressive nutritional interventions.
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TABLES
Table 1: Growth parameters as measured by standard deviation scores compared 
to the general population.
* For individuals > 36 months old, head circumference Z-scores were calculated using 
data from Roche, Mukherjee, Guo, & Moore, 1987 (Roche, A. F., Mukherjee, D., Guo, 
S. M., & Moore, W. M. (1987). Head circumference reference data: Birth to 18 years. 
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Pediatrics, 79(5), 706–712) rounding to the nearest age for which data is available, and 
using a cutoff of 18 years for patients above this age.
Table 2. Growth parameters expressed as absolute values.
For adult individuals, head circumference was plotted using charts from Rollins et al. 
(Rollins, J. D., Collins, J. S., & Holden, K. R. (2010). United States head circumference 
growth reference charts: Birth to 21 years. The Journal of Pediatrics, 156(6), 907-
913.e2.)
FIGURE TITLES AND LEGENDS:
Figure 1. Growth in Saul-Wilson syndrome.
(A) Length-for-age 0-3 years. (B) Height-for-age 3-12.5 years. (C) Weight-for-age 0-3 
years. (D) Weight-for-age 3-12.5 years. (E) Head circumference-for-age 0-3 years. PI: 
Prediction interval (used for the affected population), calculated using standard 
deviations, gives a sense of the probability that a new data point will lie within the 
indicated region. CI: Confidence interval (used for the normative population), calculated 
using standard errors, gives a sense of the probability that the mean from a new subject 
will lie within the indicated region.
Figure 2. Weight-for-length and weight velocity in Saul-Wilson syndrome.
(A) Weight-for-length 0-2.5 years. (B) Weight velocity 0-3 years. PI: Prediction interval; 
CI: Confidence interval.
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Figure 3. Effect of human growth hormone (HGH) in Saul-Wilson syndrome.
Subject Pre: height-for-age model fit for that particular subject before initiation of HGH. 
Subject Post: height-for-age model fit for the same subject after initiation of HGH. No 
HGH Treatment: height-for-age model fit for subjects who never received HGH 
supplementation. Pre HGH Treatment: Height-for-age model fit before initiation of HGH 
supplementation for subjects who eventually received this therapy. No real difference is 
observed between the last two fits, or between pre-HGH and post-HGH model fits for 
each individual subject.
SUPPORTING INFORMATION:
Figure S1. Length-for-age 0-3 years.
Figure S2. Height-for-age 3-12.5 years.
Figure S3. Weight-for-age 0-3 years.
Figure S4. Weight-for-age 3-12.5 years.
Figure S5. Head circumference-for-age 0-3 years.
Figure S6. Head circumference-for-age 3-9 years.
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(CDC*)




Range n Mean 
± SD
Range n Mean 
± SD
























































Page 16 of 57
John Wiley & Sons, Inc.






























































At birth At skeletal maturity 




44.1 ± 3.6 38.0 to 
49.0
12 34 3/7-week neonate 
(males); 32 6/7-week 
neonate (females)
107.6 ± 1.9 106 to 
109.7
3 4y 6m (male); 5y 
1m (females)
Weight (kg) 2.09 ± 0.42 1.45 to 
2.80
14 33 5/7-week neonate 
(males); 33 3/7-week 
neonate (females)
30.5 ± 7.4 25.3 to 
39.0
3 11y 9m (male); 
8y 3m (females)
OFC (cm) 31.7 ± 1.6 29.0 to 
34.0
11 35 2/7-week neonate 
(males); 34 2/7-week 
neonate (females)
50.2 ± 1.7 49.0 to 
51.4
2 4.5y (females*) 
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Figure 1. Growth in Saul-Wilson syndrome.(A) Length-for-age 0-3 years. (B) Height-for-age 3-12.5 years. 
(C) Weight-for-age 0-3 years. (D) Weight-for-age 3-12.5 years. (E) Head circumference-for-age 0-3 years. 
PI: Prediction interval (used for the affected population), calculated using standard deviations, gives a sense 
of the probability that a new data point will lie within the indicated region. CI: Confidence interval (used for 
the normative population), calculated using standard errors, gives a sense of the probability that the mean 
from a new subject will lie within the indicated region. 
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Figure 2. Weight-for-length and weight velocity in Saul-Wilson syndrome. (A) Weight-for-length 0-2.5 years. 
(B) Weight velocity 0-3 years. PI: Prediction interval; CI: Confidence interval. 
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Figure 3. Effect of human growth hormone (HGH) in Saul-Wilson syndrome. Subject Pre: height-for-age 
model fit for that particular subject before initiation of HGH. Subject Post: height-for-age model fit for the 
same subject after initiation of HGH. No HGH Treatment: height-for-age model fit for subjects who never 
received HGH supplementation. Pre HGH Treatment: Height-for-age model fit before initiation of HGH 
supplementation for subjects who eventually received this therapy. No real difference is observed between 
the last two fits, or between pre-HGH and post-HGH model fits for each individual subject. 
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